A carefully planned and executed intellectual property (IP) strategy, including ensuring appropriate IP coverage exists and identifying and pursuing opportunities for new IP, can be critical for both development and financing efforts, regardless of organization size and stage of development.

DHC offers intellectual property expertise combined with extensive technical knowledge of the Cell and Gene Therapy (C&GT) space to optimally guide and inform our clients’ IP strategy, whether to support in-house process, device or other technology development or as a part of IP commercialization activities or due diligence in connection with M&A.
Some of the IP services we offer* include:

Strategic Portfolio Assessment and Analysis:
We can help assess…

  • whether the existing IP covers and protects commercial or soon to be commercialized product
  • opportunities for additional filings
  • “holes” in IP coverage
  • licensing opportunities
  • “deadweight” IP that costs money to maintain but offers little value/limited protection/limited life

Landscape Analysis, Competitive Intelligence:
We can assist you in surveying a particular industry or therapeutic or technological area of interest for existing third-party IP as well as opportunities for new IP filings.

IP Due Diligence:
We are frequently called upon by investors to perform due diligence on companies in the C&GT space, including diligence on the IP assets. Alternatively, for companies seeking investment, our mock diligence service can help ensure you are prepared for questions investors may raise.

IP Strategy:
We can help you evaluate potential ways to protect your technology, including determining at what stage to seek IP protection.

*Please note that DHC is not a law firm and accordingly we do not provide legal services, including patent drafting and patent prosecution before the USPTO.

A carefully planned and executed intellectual property (IP) strategy, including ensuring appropriate IP coverage exists and identifying and pursuing opportunities for new IP, can be critical for both development and financing efforts, regardless of organization size and stage of development.

DHC offers intellectual property expertise combined with extensive technical knowledge of the Cell and Gene Therapy (C&GT) space to optimally guide and inform our clients’ IP strategy, whether to support in-house process, device or other technology development or as a part of IP commercialization activities or due diligence in connection with M&A.
Some of the IP services we offer* include:

Strategic Portfolio Assessment and Analysis:
We can help assess…

  • whether the existing IP covers and protects commercial or soon to be commercialized product
  • opportunities for additional filings
  • “holes” in IP coverage
  • licensing opportunities
  • “deadweight” IP that costs money to maintain but offers little value/limited protection/limited life

Landscape Analysis, Competitive Intelligence:
We can assist you in surveying a particular industry or therapeutic or technological area of interest for existing third-party IP as well as opportunities for new IP filings.

IP Due Diligence:
We are frequently called upon by investors to perform due diligence on companies in the C&GT space, including diligence on the IP assets. Alternatively, for companies seeking investment, our mock diligence service can help ensure you are prepared for questions investors may raise.

IP Strategy:
We can help you evaluate potential ways to protect your technology, including determining at what stage to seek IP protection.

*Please note that DHC is not a law firm and accordingly we do not provide legal services, including patent drafting and patent prosecution before the USPTO.

We use cookies to help give you the best experience on our website. By continuing you agree to our use of cookies.